特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
市場調査レポート
商品コード
945236

嚢胞性線維症治療薬の世界市場: 業界の動向、シェア、市場規模、成長性、機会、予測:2020年-2025年

Cystic Fibrosis Therapeutics Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2020-2025

出版日: | 発行: IMARC Services Private Limited | ページ情報: 英文 108 Pages | 納期: 2-3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=105.45円
嚢胞性線維症治療薬の世界市場: 業界の動向、シェア、市場規模、成長性、機会、予測:2020年-2025年
出版日: 2020年06月18日
発行: IMARC Services Private Limited
ページ情報: 英文 108 Pages
納期: 2-3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の嚢胞性線維症治療薬市場は、2014年から2019年にかけておよそ15%のCAGRで成長しました。嚢胞性線維症(CF)は、消化管と気道でのナトリウムと塩化物の異常な動きを特徴とする、進行性の希少遺伝性疾患です。この疾患は、肺、膵臓、腸、肝臓で粘性の分泌物を発生させる可能性があり、管理と治療には、理学療法、遺伝子療法、理学療法、栄養補給などが用いられます。また膵酵素サプリメント、粘液溶解薬、気管支拡張薬、嚢胞性線維症膜貫通コンダクタンス制御因子(CFTR)モジュレーターなどの治療薬や遺伝子療法も、細胞の相互作用や症状の改善のため使用されます。CFの発症率は世界的に上昇しており、疾患の診断技術の向上とも相まって、市場の成長を牽引する重要な要因となっています。また、代替治療としての嚢胞性線維症膜貫通コンダクタンス(CFTR)調節因子などの遺伝子療法の普及、個別化された薬物療法、分子補綴の開発、有効性が改善された革新的な薬物の開発といった技術面の進歩も市場の成長を促す要因となります。

当レポートは、世界の嚢胞性線維症治療薬市場を調査したもので、市場の概要、薬剤クラス別、薬物分子タイプ別、投与経路別、エンドユーザー別、地域別の分析、業界やバリューチェーンの分析、価格指標、競合情勢、主要企業のプロファイルなどの情報を提供しています。

目次

第1章 序文

第2章 調査範囲と手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

第5章 世界の市場

  • 市場の概要
  • 市場の実績

第6章 薬剤クラス別の市場分析

  • 膵酵素サプリメント
  • 粘液溶解薬
  • 気管支拡張薬
  • CFTR調節因子
  • 抗生物質
  • その他

第7章 薬物分子タイプ別の市場分析

  • 低分子薬
  • 生物製剤

第8章 投与経路別の市場分析

  • 経口薬
  • 吸入薬

第9章 エンドユーザー別の市場分析

  • 病院
  • クリニック
  • その他

第10章 地域別の市場分析

  • 北米
    • 米国
    • カナダ
  • アジア太平洋
    • 中国
    • 日本
    • インド
    • 韓国
    • オーストラリア
    • インドネシア
    • その他
  • 欧州
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • スペイン
    • ロシア
    • その他
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • その他
  • 中東・アフリカ

第11章 SWOT分析

第12章 バリューチェーン分析

第13章 ポーターのファイブフォース分析

第14章 価格指標

第15章 競合情勢

  • 市場の構造
  • 主な企業
  • 主な企業のプロファイル
    • Abbvie Inc.
    • Alaxia
    • Alcresta Therapeutics Inc.
    • Allergan
    • AstraZeneca
    • F. Hoffmann-La Roche Ltd
    • Gilead Sciences Inc.
    • Merck & Co., Inc.
    • Novartis AG
    • Teva Pharmaceutical Industries Ltd.
    • Vertex Pharmaceuticals Inc.
図表

List of Figures

  • Figure 1: Global: Cystic Fibrosis Therapeutics Market: Major Drivers and Challenges
  • Figure 2: Global: Cystic Fibrosis Therapeutics Market: Sales Value (in Billion US$), 2014-2019
  • Figure 3: Global: Cystic Fibrosis Therapeutics Market: Breakup by Drug Class (in %), 2019
  • Figure 4: Global: Cystic Fibrosis Therapeutics Market: Breakup by Drug Molecule Type (in %), 2019
  • Figure 5: Global: Cystic Fibrosis Therapeutics Market: Breakup by Route of Administration (in %), 2019
  • Figure 6: Global: Cystic Fibrosis Therapeutics Market: Breakup by End-User (in %), 2019
  • Figure 7: Global: Cystic Fibrosis Therapeutics Market: Breakup by Region (in %), 2019
  • Figure 8: Global: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Billion US$), 2020-2025
  • Figure 9: Global: Cystic Fibrosis Therapeutics (Pancreatic Enzyme Supplements) Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 10: Global: Cystic Fibrosis Therapeutics (Pancreatic Enzyme Supplements) Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 11: Global: Cystic Fibrosis Therapeutics (Mucolytics) Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 12: Global: Cystic Fibrosis Therapeutics (Mucolytics) Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 13: Global: Cystic Fibrosis Therapeutics (Bronchodilators) Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 14: Global: Cystic Fibrosis Therapeutics (Bronchodilators) Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 15: Global: Cystic Fibrosis Therapeutics (CFTR Modulators) Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 16: Global: Cystic Fibrosis Therapeutics (CFTR Modulators) Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 17: Global: Cystic Fibrosis Therapeutics (Antibiotics) Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 18: Global: Cystic Fibrosis Therapeutics (Antibiotics) Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 19: Global: Cystic Fibrosis Therapeutics (Others) Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 20: Global: Cystic Fibrosis Therapeutics (Others) Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 21: Global: Cystic Fibrosis Therapeutics (Small Molecule Drugs) Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 22: Global: Cystic Fibrosis Therapeutics (Small Molecule Drugs) Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 23: Global: Cystic Fibrosis Therapeutics (Biologics) Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 24: Global: Cystic Fibrosis Therapeutics (Biologics) Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 25: Global: Cystic Fibrosis Therapeutics (Oral Drugs) Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 26: Global: Cystic Fibrosis Therapeutics (Oral Drugs) Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 27: Global: Cystic Fibrosis Therapeutics (Inhaled Drugs) Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 28: Global: Cystic Fibrosis Therapeutics (Inhaled Drugs) Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 29: Global: Cystic Fibrosis Therapeutics (Hospitals) Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 30: Global: Cystic Fibrosis Therapeutics (Hospitals) Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 31: Global: Cystic Fibrosis Therapeutics (Clinics) Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 32: Global: Cystic Fibrosis Therapeutics (Clinics) Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 33: Global: Cystic Fibrosis Therapeutics (Others) Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 34: Global: Cystic Fibrosis Therapeutics (Others) Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 35: North America: Cystic Fibrosis Therapeutics Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 36: North America: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 37: United States: Cystic Fibrosis Therapeutics Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 38: United States: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 39: Canada: Cystic Fibrosis Therapeutics Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 40: Canada: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 41: Asia Pacific: Cystic Fibrosis Therapeutics Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 42: Asia Pacific: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 43: China: Cystic Fibrosis Therapeutics Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 44: China: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 45: Japan: Cystic Fibrosis Therapeutics Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 46: Japan: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 47: India: Cystic Fibrosis Therapeutics Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 48: India: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 49: South Korea: Cystic Fibrosis Therapeutics Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 50: South Korea: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 51: Australia: Cystic Fibrosis Therapeutics Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 52: Australia: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 53: Indonesia: Cystic Fibrosis Therapeutics Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 54: Indonesia: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 55: Others: Cystic Fibrosis Therapeutics Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 56: Others: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 57: Europe: Cystic Fibrosis Therapeutics Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 58: Europe: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 59: Germany: Cystic Fibrosis Therapeutics Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 60: Germany: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 61: France: Cystic Fibrosis Therapeutics Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 62: France: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 63: United Kingdom: Cystic Fibrosis Therapeutics Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 64: United Kingdom: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 65: Italy: Cystic Fibrosis Therapeutics Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 66: Italy: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 67: Spain: Cystic Fibrosis Therapeutics Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 68: Spain: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 69: Russia: Cystic Fibrosis Therapeutics Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 70: Russia: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 71: Others: Cystic Fibrosis Therapeutics Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 72: Others: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 73: Latin America: Cystic Fibrosis Therapeutics Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 74: Latin America: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 75: Brazil: Cystic Fibrosis Therapeutics Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 76: Brazil: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 77: Mexico: Cystic Fibrosis Therapeutics Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 78: Mexico: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 79: Others: Cystic Fibrosis Therapeutics Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 80: Others: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 81: Middle East and Africa: Cystic Fibrosis Therapeutics Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 82: Middle East and Africa: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 83: Global: Cystic Fibrosis Therapeutics Industry: SWOT Analysis
  • Figure 84: Global: Cystic Fibrosis Therapeutics Industry: Value Chain Analysis
  • Figure 85: Global: Cystic Fibrosis Therapeutics Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Cystic Fibrosis Therapeutics Market: Key Industry Highlights, 2019 and 2025
  • Table 2: Global: Cystic Fibrosis Therapeutics Market Forecast: Breakup by Drug Class (in Million US$), 2020-2025
  • Table 3: Global: Cystic Fibrosis Therapeutics Market Forecast: Breakup by Drug Molecule Type (in Million US$), 2020-2025
  • Table 4: Global: Cystic Fibrosis Therapeutics Market Forecast: Breakup by Route of Administration (in Million US$), 2020-2025
  • Table 5: Global: Cystic Fibrosis Therapeutics Market Forecast: Breakup by End-User (in Million US$), 2020-2025
  • Table 6: Global: Cystic Fibrosis Therapeutics Market Forecast: Breakup by Region (in Million US$), 2020-2025
  • Table 7: Global: Cystic Fibrosis Therapeutics Market Structure
  • Table 8: Global: Cystic Fibrosis Therapeutics Market: Key Players
目次
Product Code: SR1019J37_Report

The global cystic fibrosis therapeutics market grew at a CAGR of around 15% during 2014-2019. Cystic fibrosis (CF) is a rare and progressive genetic disorder that is characterized by an abnormal movement of sodium and chloride across the gastrointestinal and respiratory tracts. This disorder can cause the development of viscous secretions in the lungs, pancreas, intestines and liver. The management and treatment of CF involve physical therapy, gene therapy, physiotherapy and nutritional support. Along with this, gene therapy and medicinal drugs, such as pancreatic enzyme supplements, mucolytics, bronchodilators and cystic fibrosis transmembrane conductance regulator (CFTR) modulators are also used for targeting cellular interactomes and symptomatic improvement. These drugs can be administered to the patient orally or by inhalation.

The rising incidence of cystic fibrosis across the globe, along with improvements in the diagnostic technologies of the disorder, is one of the key factors driving the growth of the market. Furthermore, widespread adoption of cystic fibrosis transmembrane conductance (CFTR) modulators as a treatment alternative is also providing a boost to the market growth. CFTRs are configured to regulate the flow of water and chloride through cell linings of the lungs and other organs and correct the malfunctioning protein in the body. Additionally, various technological advancements, such as the development of personalized drug therapy, molecular prosthetics and innovative drugs with improved efficacy, are acting as another growth-inducing factor. Other factors, including rising healthcare expenditures, increasing health consciousness, and awareness regarding the available treatment options for cystic fibrosis, are projected to drive the market further. Looking forward, IMARC Group expects the market to continue to exhibit strong growth during 2020-2025.

Breakup by Drug Class:

  • Pancreatic Enzyme Supplements
  • Mucolytics
  • Bronchodilators
  • CFTR Modulators
  • Antibiotics
  • Others

Breakup by Drug Molecule Type:

  • Small Molecule Drugs
  • Biologics

Breakup by Route of Administration:

  • Oral Drugs
  • Inhaled Drugs

Breakup by End-User:

  • Hospitals
  • Clinics
  • Others

Breakup by Region:

  • North America
  • United States
  • Canada
  • Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
  • Latin America
  • Brazil
  • Mexico
  • Others
  • Middle East and Africa

Competitive Landscape:

  • The report has also analysed the competitive landscape of the market with some of the key players being AbbVie Inc., Alaxia, Alcresta Therapeutics Inc., Allergan, AstraZeneca, F. Hoffmann-La Roche Ltd., Gilead Sciences Inc., Merck & Co. Inc., Novartis AG, Teva Pharmaceutical Industries Ltd., Vertex Pharmaceuticals Inc., etc.

Key Questions Answered in This Report:

  • How has the global cystic fibrosis therapeutics market performed so far and how will it perform in the coming years?
  • What are the key regional markets?
  • What is the breakup of the market based on the drug class?
  • What is the breakup of the market based on the drug molecule type?
  • What is the breakup of the market based on the route of administration?
  • What is the breakup of the market based on the end-user?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the global cystic fibrosis therapeutics market and who are the key players?
  • What is the degree of competition in the industry?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Cystic Fibrosis Therapeutics Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Market Forecast

6 Market Breakup by Drug Class

  • 6.1 Pancreatic Enzyme Supplements
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Mucolytics
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Bronchodilators
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 CFTR Modulators
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Antibiotics
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast
  • 6.6 Others
    • 6.6.1 Market Trends
    • 6.6.2 Market Forecast

7 Market Breakup by Drug Molecule Type

  • 7.1 Small Molecule Drugs
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Biologics
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast

8 Market Breakup by Route of Administration

  • 8.1 Oral Drugs
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Inhaled Drugs
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast

9 Market Breakup by End-User

  • 9.1 Hospitals
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Clinics
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Others
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Indonesia
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
    • 10.2.7 Others
      • 10.2.7.1 Market Trends
      • 10.2.7.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Indicators

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 Abbvie Inc.
      • 15.3.1.1 Company Overview
      • 15.3.1.2 Product Portfolio
      • 15.3.1.3 Financials
      • 15.3.1.4 SWOT Analysis
    • 15.3.2 Alaxia
      • 15.3.2.1 Company Overview
      • 15.3.2.2 Product Portfolio
    • 15.3.3 Alcresta Therapeutics Inc.
      • 15.3.3.1 Company Overview
      • 15.3.3.2 Product Portfolio
    • 15.3.4 Allergan
      • 15.3.4.1 Company Overview
      • 15.3.4.2 Product Portfolio
      • 15.3.4.3 Financials
      • 15.3.4.4 SWOT Analysis
    • 15.3.5 AstraZeneca
      • 15.3.5.1 Company Overview
      • 15.3.5.2 Product Portfolio
      • 15.3.5.3 Financials
      • 15.3.5.4 SWOT Analysis
    • 15.3.6 F. Hoffmann-La Roche Ltd
      • 15.3.6.1 Company Overview
      • 15.3.6.2 Product Portfolio
    • 15.3.7 Gilead Sciences Inc.
      • 15.3.7.1 Company Overview
      • 15.3.7.2 Product Portfolio
      • 15.3.7.3 Financials
      • 15.3.7.4 SWOT Analysis
    • 15.3.8 Merck & Co., Inc.
      • 15.3.8.1 Company Overview
      • 15.3.8.2 Product Portfolio
      • 15.3.8.3 Financials
      • 15.3.8.4 SWOT Analysis
    • 15.3.9 Novartis AG
      • 15.3.9.1 Company Overview
      • 15.3.9.2 Product Portfolio
      • 15.3.9.3 Financials
      • 15.3.9.4 SWOT Analysis
    • 15.3.10 Teva Pharmaceutical Industries Ltd.
      • 15.3.10.1 Company Overview
      • 15.3.10.2 Product Portfolio
      • 15.3.10.3 Financials
      • 15.3.10.4 SWOT Analysis
    • 15.3.11 Vertex Pharmaceuticals Inc.
      • 15.3.11.1 Company Overview
      • 15.3.11.2 Product Portfolio
      • 15.3.11.3 Financials
      • 15.3.11.4 SWOT Analysis
株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.